A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1 dose-escalation and expansion study that will evaluate the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of SAIL66
in patients with CLDN6-positive locally advanced or metastatic solid tumors.